Business Wire

B2BROKER

18.4.2024 18:07:28 CEST | Business Wire | Press release

Share
B2Broker Increases Leverage on Major FX Pairs to 1:200

Leading Prime of Prime liquidity provider B2Broker is committed to quality, always listening to their clients' needs to provide them with the best possible tools to bring in more end users and gain a competitive edge in the industry. In this regard, B2Broker announces the rise of the leverage to 1:200 for major FX pairs, thereby reducing the margin requirements from 1% to 0.5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418556608/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2Broker increases leverage on major FOREX pairs to 1:200 and to 1:50 for BTC/USD and ETH/USD pairs, enhancing the market position of their clients. (Graphic: Business Wire)

Additionally, with the cryptocurrency market thriving and traders’ demands for higher leverage growing, the company has increased leverage up to 1:50 for BTCUSD and ETHUSD, reducing margin requirements from 10% to 2% and significantly enhancing the clients' market position.

Additional Information about B2Broker Liquidity Solutions

Having been in the industry for over a decade, B2Broker's liquidity solutions have significantly expanded. They currently offer over 1500 instruments across 8 asset classes, including FOREX, Crypto CFD, Spot Indices, Precious Metals, Single Stocks, ETFs, Commodities, and NDFs CFD.

B2Broker ensures access to deep liquidity pools from Tier-1 providers, facilitating tight spreads and ultra-fast execution. Advanced technology platforms and FIX API integrations like B2Trader, cTrader, oneZero, Prime XM, Centroid, TFB, TradeLocker, Your Bourse, FX Cubic, and MT4/MT5 allow for seamless connectivity across multiple trading systems. The infrastructure of B2Broker facilitates the distribution and aggregation of liquidity through various channels, enhancing trade execution and reducing risk.

The key strengths of the liquidity solutions include a robust infrastructure, extensive connectivity options, and the ability to develop customised liquidity setups to meet the client’s demands.

As an industry leader, B2Broker has introduced multiple innovative solutions throughout its journey. Last year, the company introduced NDFs as a new asset class in the form of CFDs, with the advantage of next-day settlements. Furthermore, they were the first in the market to introduce crypto CFDs based on spot and then perpetual futures LPs. And now, B2Broker proudly offers the most competitive margin conditions on the market!

The company has significantly strengthened its balance sheet by serving over 250 institutional clients and 30 professional funds. Because of this strong financial base, it has been able to expand leverage and meet clients' requests.

With the increased leverage on highly demanded trading pairs in key markets such as FX and Crypto, the company empowers brokers to give their traders greater flexibility in managing their capital, significantly broadening the client’s appeal to a larger user base.

John Murillo, Chief Dealing Officer of B2Broker Group of Companies, remarked:

“This strategic update not only enhances our clients' competitive edge but also augments their capacity to cater to the evolving demands of their clientele, attract new business, and elevate their service standards by leveraging our liquidity solutions.

Thanks to our robust balance sheet and extensive client base, coupled with our impressive trading volumes, we stand at the forefront of the market. Our innovative mindset has been evident throughout our journey. We were the first to introduce crypto CFDs based on spot and, later, on perpetual futures. In addition to FOREX, today, we proudly offer over 150 crypto CFD pairs, a testament to our commitment to innovation and meeting the diverse needs of our clients.”

Final Remarks

B2Broker is a distinguished leader in the FinTech sector, revolutionising the industry with significant contributions over the last decade. With a dedication to innovation and continuous improvement, the company guarantees that its clients stay ahead of the competition and set trends alongside it. Their vast ecosystem provides solutions that suit various business models.

In the latest update, B2Broker has substantially upgraded the leverage to provide the most competitive conditions for institutional clients, professional traders, brokerages, hedge funds, proprietary trading desks, and other financial institutions.

Contact B2Broker today for tailored solutions that drive success!

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418556608/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye